Phase 2 Trial of Carfilzomib for Metastatic Castration-resistant Prostate Cancer Following Treatment
Status:
Completed
Trial end date:
2017-07-14
Target enrollment:
Participant gender:
Summary
This study will test how effective the drug, Carfilzomib, reduces progression of prostate
cancer in patients who have previously received chemotherapy and androgen inhibitors.
Carfilzomib is approved for multiple myeloma but is not approved for prostate cancer.
Therefore, it is considered investigational. Other approved methods of treatment for
metastatic prostate cancer have demonstrated only modest benefits. Novel and tolerable agents
are necessary to make further gains and extend overall survival.